We noticed you’re blocking ads

Thanks for visiting CRSToday. Our advertisers are important supporters of this site, and content cannot be accessed if ad-blocking software is activated.

In order to avoid adverse performance issues with this site, please white list https://crstoday.com in your ad blocker then refresh this page.

Need help? Click here for instructions.

Innovations | Aug 2010


Macaluso Pull-Through System
The Macaluso Pull-Through System (Oasis Medical, Inc., Glendora, CA) is designed for inserting the endothelial graft. According to the company, this system does not require viscoelastic, which avoids interfacerelated issues caused by the presence of viscoelastic between the graft and host tissue. The loading platform is designed to eliminate the chance of tissue’s folding onto itself during loading of the inserter. The inserter’s closed design reportedly reduces the chance of the chamber’s collapse, allows for quicker and more precise positioning of the graft, and keeps fluid from rushing over the graft and damaging endothelial cells. According to the company, the titaniuminserting device with a lateral winglet allows the endothelial lenticle to be easily grasped by the loading and positioning forceps. The rubbertipped plunger reportedly creates a seal that stabilizes pressure in the anterior chamber to avoid collapse.

The FDA has approved the gatifloxacin ophthalmic solution Zymaxid 0.5% (Allergan, Inc., Irvine, CA). Zymaxid is a topical fluoroquinolone anti-infective for the treatment of bacterial conjunctivitis caused by susceptible strains of Haemophilus influenzae, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus mitis group, Streptococcus oralis<, and Streptococcus pneumoniae. The product is currently the highestconcentration gatifloxacin ophthalmic solution on the US market, according to the company.

Bausch + Lomb (Rochester, NY) announced the US launch of PreserVision Eye Vitamin and Mineral Supplement Age-Related Eye Disease Study (AREDS) 2 formula, a high-potency antioxidant supplement with vitamins and minerals. The new formula builds on the original, clinically proven AREDS formula, but it replaces beta-carotene with 10 mg of lutein and 2 mg of zeaxanthin and adds 1,000 mg of omega-3 fatty acids per daily dosage. The AREDS 2 study is designed to determine whether a combination of vitamins and minerals can slow the progression of vision loss from agerelated macular degeneration and is expected to be completed in 2013. PreserVision is currently available at retail locations.

Advertisement - Issue Continues Below
Publication Ad Publication Ad
End of Advertisement - Issue Continues Below

Aug 2010